SCHEMBL4966150

SCHEMBL4966150

COc1cc2ncnc(N3CCC(NC(=O)Nc4ccc(Cl)cc4)CC3)c2cc1OC

nearest known ligand 0.70

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 15/20 0.70
PDGFRA P16234 7/20 0.70
KIT P10721 4/20 0.59
KDR P35968 1/20 0.59
PAK1 Q13153 1/20 0.58
FLT3 P36888 2/20 0.58
ENPP1 P22413 1/20 0.57
ACHE P22303 1/20 0.56
BACE1 P56817 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4967719 0.94 PDGFRB (0.65) PDGFRBPDGFRAKITKDRFLT3
SCHEMBL4966832 0.91 PDGFRB (0.71) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4966896 0.89 PDGFRA (0.57) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4969629 0.89 PDGFRA (0.60) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4965855 0.87 PDGFRB (0.72) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4969305 0.87 PDE10A (0.61) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4974993 0.87 PDGFRA (0.64) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4965795 0.85 PDGFRB (0.66) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4969927 0.85 ENPP1 (0.55) PDGFRBPDGFRAKITKDRPAK1
SCHEMBL4966363 0.84 PDGFRA (0.56) PDGFRBPDGFRAKITKDRPAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101300249-A Aminoquinoline and aminoquinazoline kinase modulators JANSSEN PHARMACEUTICA NV (BE) 2008-11-05 CN disclosed
CN-101242838-A Synergistic modulation of FLT3 kinase using aminoquinoline and aminoquinazoline kinase modulators JANSSEN PHARMACEUTICA NV (BE) 2008-08-13 CN disclosed
EP-1899319-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
EP-1893206-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135649-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135636-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, CDC42BPG, PRKCQ PDGFRB 284/4885PDGFRA 460/4885KIT 197/4885
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, BMX, ABL1 PDGFRB 51/4885PDGFRA 74/4885KIT 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.